Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
14(44%)
Results Posted
0%(0 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_1
2
6%
Ph phase_2
8
25%
Ph phase_3
11
34%
Ph not_applicable
2
6%
Ph phase_4
7
22%

Phase Distribution

2

Early Stage

8

Mid Stage

18

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
2(6.7%)
Phase 2Efficacy & side effects
8(26.7%)
Phase 3Large-scale testing
11(36.7%)
Phase 4Post-market surveillance
7(23.3%)
N/ANon-phased studies
2(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

14

trials recruiting

Total Trials

32

all time

Status Distribution
Active(21)
Completed(3)
Terminated(3)
Other(5)

Detailed Status

Recruiting13
Not yet recruiting7
unknown5
Completed3
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
14
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (6.7%)
Phase 28 (26.7%)
Phase 311 (36.7%)
Phase 47 (23.3%)
N/A2 (6.7%)

Trials by Status

withdrawn13%
completed39%
not_yet_recruiting722%
recruiting1341%
active_not_recruiting13%
unknown516%
terminated26%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT06456580Phase 3

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Recruiting
NCT07404865Phase 3

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Recruiting
NCT07522099Phase 2

Chinese Adults With Kidney Disease

Recruiting
NCT07495033Phase 3

Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

Not Yet Recruiting
NCT07249632Phase 3

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Recruiting
NCT07340463Phase 2

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting
NCT05687526Phase 1

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Completed
NCT07298928Not Applicable

A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

Not Yet Recruiting
NCT06456567Phase 3

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Withdrawn
NCT05306574Phase 3

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Terminated
NCT05799287Phase 3

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Active Not Recruiting
NCT07052981Phase 3

Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis

Not Yet Recruiting
NCT05078710Phase 2

Telitacicept in Primary APS Patients

Terminated
NCT07008196Phase 4

Telitacicept for the Treatment of Refractory RA

Not Yet Recruiting
NCT05737160Phase 3

Study of Telitacicept in Generalized Myasthenia Gravis

Completed
NCT05998759Phase 2

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting
NCT06375005Phase 2

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting
NCT06723548Phase 4

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Not Yet Recruiting
NCT06614985Phase 2

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Not Yet Recruiting
NCT06125405Phase 3

Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome

Recruiting

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
32